← Back to all research
Rapamycin (sirolimus), an immunosuppressant used in organ transplantation, is the only drug consistently shown to extend lifespan in every mammal tested. It does so by inhibiting mTORC1—a master growth sensor that, when chronically elevated, accelerates aging. The evidence for longevity is exceptional in animals. Human off-label use is growing among longevity physicians. But immunosuppression risks and limited long-term human data demand careful consideration.
Evidence Assessment
Evidence Strength
Strong
Study Type
Preclinical + Clinical Evidence
Confidence
High
Key Findings
- Rapamycin extended mouse lifespan 10-18% even when started at 20 months (equivalent to age 60 in humans)
- Low-dose everolimus (rapalogue) improved influenza vaccine response 20% in older humans (Mannick et al., Science Translational Medicine 2018)
- Intermittent weekly dosing may provide lifespan benefits with lower immunosuppression risk
- Dog Aging Project showed improved cardiac function with 3mg/week in older dogs
Practical Takeaways
- Only pursue with physician supervision and prescription—not available OTC
- If using: 3-10mg orally once per week is the longevity protocol range studied
- Monitor: fasting glucose, lipids, CBC regularly; avoid grapefruit
Limitations & Caveats
- No long-term RCT in healthy humans
- Immunosuppression risk at higher doses is real
- Requires prescription and medical supervision